Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience.

ABSTRACT:

Background

Infliximab (IFX) infusion may lead to development of anti-IFX antibodies, and subsequent infusion reactions (IRs). The safety of rapid IFX infusion administered over 60 minutes has been under-investigated in children with inflammatory bowel disease. In a multicenter study, the frequency and nature of rapid infusion-associated IRs were examined.

Methods

The medical records of all consecutive children with inflammatory bowel disease receiving rapid IFX infusions between January 2014 and December 2016 were reviewed. Poisson regression analysis was used to identify possible associated factors with IRs.

Results

A total of 4120 rapid infusions for 453 children (median age 16 yrs [interquartile range 13.8-17.8], 289 males, 374 with Crohn's disease) were included.

SUBMITTER: El-Matary W 

PROVIDER: S-EPMC6551232 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature